================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15 (d)
of the Securities Exchange Act of 1934
For the Quarterly Period Ended September 30, 2007
Commission File Number 0-13839
CAS MEDICAL SYSTEMS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 06-1123096
--------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
44 East Industrial Road, Branford, Connecticut 06405
--------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
(203) 488-6056
--------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one):
Large Accelerated Filer [_] Accelerated Filer [_] Non-Accelerated Filer [X]
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [_] No [X]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: Common Stock, $.004 par value
10,890,285 shares as of November 1, 2007.
================================================================================
Page 2
INDEX
PART 1 Financial Information Page No.
------ --------------------- --------
Item 1 Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets as of
September 30, 2007 and December 31, 2006 3
Condensed Consolidated Statements of Income for the
Three and Nine Months Ended September 30, 2007 and 2006 5
Condensed Consolidated Statements of Cash Flow for
the Nine Months Ended September 30, 2007 and 2006 6
Notes to Condensed Consolidated Financial Statements 7
Item 2 Management's Discussion and Analysis of Financial
Condition and Results of Operations 12
Item 3 Quantitative and Qualitative Disclosures about Market
Risk 17
Item 4T Controls and Procedures 17
PART II Other Information
------- -----------------
Item 1 Legal Proceedings 18
Item 6 Exhibits 18
Signatures 19
Page 3
PART I - FINANCIAL INFORMATION
------------------------------
ITEM 1. FINANCIAL STATEMENTS
-----------------------------
CAS Medical Systems, Inc.
Condensed Consolidated Balance Sheets
-------------------------------------
(Unaudited)
Assets September 30, December 31,
------ 2007 2006
------------ ------------
Current Assets:
Cash and cash equivalents $ 698,655 $ 1,334,535
Accounts receivable, net of allowance 6,339,198 4,906,303
Inventories 10,915,227 6,808,193
Deferred income taxes 511,026 329,458
Recoverable income taxes 508 320,943
Other current assets 533,519 408,171
------------ ------------
Total current assets 18,998,133 14,107,603
Property, plant and equipment 5,832,400 6,859,759
Accumulated depreciation (3,439,934) (3,535,915)
------------ ------------
2,392,466 3,323,844
Intangible and other assets, net 676,549 457,352
Goodwill 3,379,021 3,379,021
Deferred income taxes 751,584 175,611
------------ ------------
Total assets $ 26,197,753 $ 21,443,431
============ ============
Page 4
CAS Medical Systems, Inc.
Condensed Consolidated Balance Sheets
-------------------------------------
(Unaudited)
September 30, December 31,
Liabilities and Stockholders' Equity 2007 2006
------------------------------------ ------------ ------------
Current Liabilities:
Current portion of long-term debt $ 568,783 $ 609,615
Line-of-credit 1,200,384 --
Notes payable 137,969 69,241
Accounts payable 5,653,122 3,228,265
Accrued expenses 1,053,402 1,104,726
------------ ------------
Total current liabilities 8,613,660 5,011,847
Other liabilities 134,375 --
Deferred gain on sale/leaseback of property 1,347,275 --
Long-term debt, less current portion 2,470,436 3,806,587
Stockholders' Equity:
Series A cumulative convertible preferred
stock, $.001 par value per share,
1,000,000 shares authorized, shares
issued or outstanding - none -- --
Common stock, $.004 par value per share,
40,000,000 shares authorized, 10,976,285
and 10,679,307 shares issued at September
30, 2007 and December 31, 2006,
respectively, including shares held in
treasury 43,565 42,717
Treasury stock - 86,000 shares (101,480) (101,480)
Additional paid-in capital 5,758,060 4,935,538
Retained earnings 7,931,862 7,748,222
------------ ------------
Total stockholders' equity 13,632,007 12,624,997
------------ ------------
Total liabilities and stockholders' equity $ 26,197,753 $ 21,443,431
============ ============
See accompanying notes.
Page 5
CAS Medical Systems, Inc.
Condensed Consolidated Statements of Income
-------------------------------------------
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------------- ----------------------------
2007 2006 2007 2006
------------ ------------ ------------ ------------
NET SALES: $ 10,663,435 $ 9,425,508 $ 27,915,163 $ 25,011,449
COST OF SALES: 6,634,787 5,340,278 17,830,189 14,508,725
OPERATING EXPENSES:
Research and development 439,861 653,221 1,725,261 1,886,352
Selling, general and administrative 2,937,840 2,262,016 7,920,957 6,457,098
------------ ------------ ------------ ------------
3,377,701 2,915,237 9,646,218 8,343,450
------------ ------------ ------------ ------------
OPERATING INCOME 650,947 1,169,993 438,756 2,159,274
Interest expense 71,455 59,562 189,382 187,272
------------ ------------ ------------ ------------
Income before income taxes 579,492 1,110,431 249,374 1,972,002
Income taxes /(benefit) 40,298 390,525 (68,641) 761,000
------------ ------------ ------------ ------------
NET INCOME $ 539,194 $ 719,906 $ 318,015 $ 1,211,002
============ ============ ============ ============
EARNINGS PER COMMON SHARE:
Basic $ 0.05 $ 0.07 $ 0.03 $ 0.12
============ ============ ============ ============
Diluted $ 0.05 $ 0.06 $ 0.03 $ 0.10
============ ============ ============ ============
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING:
Basic 10,749,947 10,461,615 10,675,483 10,354,621
============ ============ ============ ============
Diluted 11,982,011 12,094,349 12,094,725 12,166,806
============ ============ ============ ============
See accompanying notes.
Page 6
CAS Medical Systems, Inc.
Condensed Consolidated Statements of Cash Flow
----------------------------------------------
(Unaudited)
Nine Months Ended
September 30
-----------------------------
2007 2006
------------ ------------
OPERATING ACTIVITIES:
Net income $ 318,015 $ 1,211,002
Adjustments to reconcile net income
to net cash (used) provided by operating
activities:
Depreciation and amortization 567,990 366,942
Deferred income taxes (757,541) 33,800
Provision for doubtful accounts 75,000 10,436
Non-cash stock compensation 217,517 298,854
Amortization of deferred gain on
sale/leaseback of property (9,422) --
Changes in operating assets and liabilities:
Accounts receivable (1,507,895) (2,114,019)
Inventories (4,107,034) (827,579)
Other current assets (125,348) 119,166
Recoverable income taxes 320,435 --
Retirement benefit obligation -- (262,176)
Accounts payable and accrued expense 2,373,533 1,211,805
------------ ------------
Net cash (used) provided by operating
activities (2,634,750) 48,231
------------ ------------
INVESTING ACTIVITIES:
Purchase of property and equipment (1,012,607) (637,923)
Proceeds from sale of property 2,801,852 --
Business acquisition, net of cash acquired
of $250,000 -- (300,000)
Purchase of intangible assets (288,358) (142,057)
------------ ------------
Net cash provided (used) by investing
activities 1,500,887 (1,079,980)
------------ ------------
FINANCING ACTIVITIES:
Repayments of long-term debt (1,376,983) (401,155)
Proceeds from notes payable 329,011 245,467
Repayments of notes payable (260,283) (427,201)
Borrowings from line-of-credit, net 1,200,384 --
Tax benefits from exercise of warrants 379,811 --
Proceeds from issuance of common stock 226,043 417,597
------------ ------------
Net cash provided (used) by financing
activities 497,983 (165,292)
------------ ------------
Change in cash and cash equivalents (635,880) (1,197,041)
Cash and cash equivalents, beginning of period 1,334,535 1,892,584
------------ ------------
Cash and cash equivalents, end of period $ 698,655 $ 695,543
============ ============
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for interest $ 191,980 $ 186,530
Cash paid (collected) during the period for
income taxes, net $ (11,346) $ 414,943
See accompanying notes.
Page 7
CAS Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
September 30, 2007
(1) The Company
CAS Medical Systems, Inc. ("CAS") and its wholly-owned subsidiary,
Statcorp, Inc. ("Statcorp") operate as one reportable business segment.
Together, CAS and Statcorp (collectively, the "Company" or "CASMED") develop,
manufacture and distribute diagnostic equipment and medical products for use in
the healthcare and medical industry. These products - specifically blood
pressure measurement technology, vital signs measurement equipment,
cardio-respiratory monitoring equipment, cerebral oximetry monitoring, and
supplies for neonatal intensive care - are sold by CASMED through its own sales
force, via distributors and pursuant to original equipment manufacturer
agreements both internationally and in the United States. The Company has
several other products in various stages of development that it believes will
add to and complement its current product lines.
(2) Basis of Presentation
The financial statements included herein have been prepared, without
audit, pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information and disclosures included in financial statements
prepared in accordance with accounting principles generally accepted in the
United States of America have been condensed or omitted pursuant to such rules
and regulations. These condensed consolidated financial statements should be
read in conjunction with the financial statements and notes thereto included in
the Company's Annual Report filed on Form 10-KSB for the year ended December 31,
2006. The condensed consolidated balance sheet as of December 31, 2006 was
derived from the audited financial statements for the year then ended.
In the opinion of the Company, all adjustments (consisting of normal
recurring accruals) necessary to present fairly the financial position of the
Company and the results of its operations and its cash flows have been included
in the accompanying financial statements. The results of operations for interim
periods are not necessarily indicative of the expected results for the full
year.
(3) Principal Products and Services
Effective in the third quarter of 2007, the Company has categorized its
sales of products and services into the following categories:
a) High acuity products - includes sales of the Fore-Sight(R) cerebral
monitor and accessories.
b) Low acuity products - includes sales of cardio-respiratory monitors and
accessories used to monitor apnea in home-based and hospital settings; the
Company's dual platform of vital signs monitors and accessories
incorporating various combinations of measurement parameters for both
human and veterinary use including pulse oximetry, electro-cardiography,
temperature, non-invasive blood pressure, and capnography; co-branded
products developed and manufactured by Analogic Corporation including
vital signs monitors utilizing parameters as described above and
additionally monitors which measure non-invasive cardiac output and
hemodynamic status, and fetalgard monitors.
c) Blood Pressure Measurement Technology - includes sales to Original
Equipment Manufacturers ("OEM") of the Company's proprietary non-invasive
blood pressure modules (MAXNIBP(R)), blood pressure cuffs and accessories
for the OEM market and related license fees.
d) Supplies and Service - includes sales of blood pressure cuffs and rapid
infusor cuffs, neonatal intensive care supplies including electrodes and
skin temperature probes, and service repair revenues.
Page 8
(4) Inventories
Inventories consisted of:
September 30, December 31,
2007 2006
------------ ------------
Raw materials $ 7,827,431 $ 5,161,884
Work-in-process 325,347 99,663
Finished goods 2,762,449 1,546,646
$ 10,915,227 $ 6,808,193
============ ============
(5) Warranty Costs
The Company warranties its products for up to three years; such costs are
not material to these financial statements.
(6) Earnings per Common Share
A summary of the denominators used to compute basic and diluted earnings
per share follows:
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------------- ---------------------------
2007 2006 2007 2006
------------ ------------ ------------ ------------
Weighted average shares outstanding, net
of restricted shares - used to compute
basic earnings per share 10,749,947 10,461,615 10,675,483 10,354,621
Dilutive effect of restricted shares, and
outstanding warrants and options 1,232,164 1,632,734 1,419,242 1,812,185
------------ ------------ ------------ ------------
Weighted average shares of dilutive
securities outstanding - used to compute
diluted earnings per share 11,982,111 12,094,349 12,094,725 12,166,806
============ ============ ============ ============
(7) Stock-Based Compensation
Stock compensation expense was $86,383 and $97,687 and $217,517 and
$298,854 for the three-month and nine-month periods ended September 30, 2007 and
September 30, 2006, respectively.
As of September 30, 2007, the unrecognized stock-based compensation cost
related to non-vested stock awards was $737,606. Such amount, reduced for
forfeiture related estimates, will be recognized in operations over a weighted
average period of 2.29 years.
Page 9
The following table summarizes the Company's stock option information as
of, and for the nine-month period ended September 30, 2007:
Weighted-
Average
Weighted- Contractual
Average Aggregate Life
Option Exercise Intrinsic Remaining
Shares Price Value (1) in Years
---------- ---------- ---------- ----------
Outstanding at December 31, 2006 537,650 $ 1.98
Granted at fair value 15,000 4.53
Exercised (25,725) 1.47
----------
Outstanding at September 30, 2007 526,925 2.11 $ 3.24 6.71
Exercisable at September 30, 2007 499,425 $ 1.95 $ 3.40 6.57
(1) The intrinsic value of a stock option is the amount by which the
current market value of the underlying stock exceeds the option exercise price.
The exercise period for all outstanding stock options may not exceed ten
years from the date of grant. Stock options granted to employees and
non-employee directors vest ratably not less than two years from the grant date.
The Company attributes stock-based compensation cost to operations using the
straight-line method over the applicable vesting period.
The weighted-average grant date fair value of stock options granted during
the nine-month periods ended September 30, 2007 and 2006 was $4.53 and $8.83 per
share, respectively. The total intrinsic value of stock options exercised during
the nine-month periods ended September 30, 2007 and 2006 was $239,583 and
$1,230,958, respectively.
The fair value of each option granted was estimated on the date of grant
using the Black-Scholes option-pricing model with the following assumptions:
Nine Months Ended
September 30, 2007 September 30, 2006
------------------ ------------------
Weighted-average expected stock-price volatility 15.5% 32.0%
Weighted-average expected option life 4.2 years 7.0 years
Average risk-free interest rate 4.61% 4.325%
Average dividend yield 0.0% 0.0%
During July 2007, the Company issued an aggregate of 73,000 shares of
restricted stock to employees under its 2003 Equity Incentive Plan which vest
ratably over thirty-six months and 12,000 shares of restricted stock under its
2003 Equity Incentive Plan to certain members of the Board of Directors which
vest quarterly over twelve months. The market value of the 85,000 shares granted
was $6.48 on the date of grant and the aggregate fair value was $550,800.
During July 2006, the Company issued an aggregate of 55,000 shares of
restricted stock to employees under its 2003 Equity Incentive Plan which vest
thirty-six months from date of grant. During 2006, 8,000 shares were forfeited
due to employee terminations and 47,000 shares remain outstanding and non-vested
as of September 30, 2007. The weighted average value of the stock was $6.04 per
share and the aggregate fair value was $332,100.
Stock compensation expense of $607,855 has been recognized from date of
issuance to September 30, 2007 related to the foregoing shares. The unamortized
stock compensation expense, net of cancellations, associated with the foregoing
shares as of September 30, 2007 is $737,606 and will be recognized through 2010.
Page 10
During the first nine months of 2007, warrants were exercised to purchase
a total of 164,599 shares of common stock at a weighted average exercise price
of $0.45 per share. Of such warrants, 60,000 shares were exercised by a former
director of the Company and warrants to purchase 104,599 shares were exercised
by Louis P. Scheps, the Company's Chairman of the Board of Directors. On March
12, 2007, Mr. Scheps entered into a stock sale plan under Rule 10b5-1 of the
Securities Exchange Act pursuant to which Mr. Scheps may sell up to 250,000
shares of common stock from time to time prior to March 31, 2008. As of
September 30, 2007, warrants to purchase 1,064,401 shares of common stock were
outstanding at a weighted average exercise price of $0.50 per share.
(8) New Accounting Pronouncements
In February 2007, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 159, The Fair Value
Option for Financial Assets and Financial Liabilities - Including an Amendment
of FASB Statement No. 115. Under SFAS 159, a company may elect to use fair value
to measure certain financial assets and financial liabilities. The fair value
election is irrevocable and generally made on an instrument-by-instrument basis
even if a company has similar instruments that it elects not to measure at fair
value. At the adoption date, unrealized gains and losses on existing items for
which the fair value option has been elected are reported as a cumulative
adjustment to beginning retained earnings. Subsequent to the adoption of SFAS
159, changes to fair value are recognized in earnings. SFAS 159 is effective for
fiscal years beginning after November 15, 2007 and is required to be adopted by
the Company in the first quarter of 2008. The Company is currently determining
if fair value accounting is appropriate for any eligible items and cannot
currently estimate the effect, if any, which SFAS 159 will have on its
consolidated financial statements.
(9) Income Taxes
The income tax benefit of $68,641 recorded for the nine months ended
September 30, 2007 reflects an exchange of approximately $155,000 of state tax
carryforwards for reduced cash credits payable to the Company. The expected
combined federal and state effective rate approximates 31% for 2007 and is lower
than the statutory rate as a result of anticipated state and federal R&D tax
credits partially offset by non-deductible stock compensation expense. The
provision for income taxes of $761,000 for the first nine months of 2006
reflects an effective tax rate of 39% resulting primarily from non-deductible
stock compensation expense partially offset by estimated state and federal R&D
tax credits.
During the first nine months of 2007, warrants to purchase 164,599 shares
of the Company's common stock were exercised by a former outside director and a
current director of the Company. The exercise of the warrants resulted in income
tax deductions in excess of compensation expense recognized of $1,140,573. Such
amount shall be included in the taxable income of the applicable directors and
deducted by the Company for federal and state income tax reporting purposes. As
a result, the Company has reduced its federal and state income tax obligations
by $379,811 and credited additional paid-in capital.
Recoverable income taxes consist of estimated tax deposits in excess of
the current provision and the income tax effect of the warrant exercise noted
above.
On January 1, 2007, the Company adopted FASB Interpretation No. 48,
"Accounting for Uncertainty in Income Taxes - an interpretation of FASB
Statement No. 109" ("FIN 48"). FIN 48 prescribes a more-likely-than-not
threshold for financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return. This interpretation also provides
guidance on de-recognition of income tax assets and liabilities, classification
of current and deferred income tax assets and liabilities, accounting for
interest and penalties associated with tax positions, accounting for income
taxes interim periods and income tax disclosures. In conjunction with the
adoption of FIN 48, the Company recognized approximately $134,000 in uncertain
tax positions as non-current income tax liabilities and a reduction in retained
earnings.
Page 11
The Company files income tax returns in the U.S. federal and various state
jurisdictions. With few exceptions, the Company is no longer subject to U.S.
federal, state and local income tax examinations by tax authorities for years
prior to 2004. During 2006, the Company concluded an examination with U.S.
federal tax authorities for the tax year ended December 31, 2004 which resulted
in a refund to the Company.
The Company's policy is to recognize interest related to unrecognized tax
benefits as interest expense and penalties as operating expense. Accrued
interest is insignificant and there are no penalties accrued at September 30,
2007. The Company believes that it has appropriate support for the income tax
positions taken and to be taken on its tax returns and that its accruals for tax
liabilities are adequate for all open years based upon an assessment of many
factors including past experience and interpretations of tax law as applied.
The Company's adoption of FIN 48 has not affected the consolidated
financial results of operations or the cash flows of the Company.
(10) Sale and Leaseback of Property and Repayment of Mortgage Debt
On September 6, 2007, the Company closed the sale and leaseback of its
headquarters and manufacturing facility (the "Property") which comprises
approximately 24,000 square feet of office and manufacturing space. Net proceeds
from the sale were $2,801,852 of which $928,872 was used to retire the related
outstanding mortgage debt. The gain of $1,356,696 realized on the sale has been
deferred and will be recognized in operations against rent expense over the term
of the lease. The lease has an initial term of ten years expiring on September
6, 2017 and an option for two additional five-year periods. The lease provides
for an annual base rent in years one through five of $244,800 and $268,800 in
years six through ten. The Company will recognize rent expense on a
straight-line basis over the ten years. Under the lease, the Company is
responsible for the costs of utilities, insurance, taxes and maintenance
expenses. Further, the Company is required to maintain at least $600,000 in cash
and cash equivalents (increasing at 3% per annum) and net current assets of not
less than $3,600,000.
In addition, the Company has a right of first offer to lease any
additional space or building built by the lessor on the Property, subject to
certain restrictions. The Company also has the right to require the lessor to
build an addition or additional building ("Expansion Premises"), subject to
certain restrictions. Upon the delivery of any Expansion Premises, the term of
the Lease would extend for a ten year term. The base rent for the Expansion
Premises shall be the greater of the then prevailing market rent or an amount
equal to a return on actual costs of construction of the greater of 250 basis
points over the rate on ten year U.S. Treasury Notes, or 8%. Upon delivery of
the Expansion Premises, the lessor would assume obligations under the Company's
existing lease of the Property, in exchange for a payment equal to three months
rent and certain unamortized costs incurred in its two adjacent facilities.
(11) Material Commitments
Effective July 1, 2007, the Company entered into a five-year agreement to
lease approximately 13,000 square feet of office space adjacent to two of the
Company's other facilities. The lease provides for average annual base rent of
$112,500 and requires the Company to pay its proportionate share of annual
operating expenses including utilities, insurance, taxes and maintenance.
Page 12
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
------ -----------------------------------------------------------------------
OF OPERATIONS
-------------
Certain statements included in this report, including without limitation
statements in the Management's Discussion and Analysis of Financial Condition
and Results of Operations, which are not historical facts, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements represent the Company's current expectations
regarding future events. The Company cautions that such statements are qualified
by important factors that could cause actual results to differ materially from
expected results which may be contained in the forward-looking statements. All
forward-looking statements involve risks and uncertainties, including, but not
limited to, the following: foreign currency fluctuations, regulations and other
economic and political factors which affect the Company's ability to market its
products internationally, new product introductions by the Company's
competitors, increased price competition, dependence upon significant customers,
availability and cost of components for the Company's products, the impact of
any adverse litigation, marketplace acceptance for the Company's new products,
FDA and other governmental regulatory and enforcement actions, changes to
federal research and development grant programs presently utilized by the
Company and other factors described in greater detail in the Company's most
recent annual report on Form 10-KSB.
Introduction
------------
Effective in the third quarter of 2007, the Company has categorized its
sales of products and services into the following categories:
e) High acuity products - includes sales of the Fore-Sight(R) cerebral
monitor and accessories.
f) Low acuity products - includes sales of cardio-respiratory monitors and
accessories used to monitor apnea in home-based and hospital settings; the
Company's dual platform of vital signs monitors and accessories
incorporating various combinations of measurement parameters for both
human and veterinary use including pulse oximetry, electro-cardiography,
temperature, non-invasive blood pressure, and capnography; co-branded
products developed and manufactured by Analogic Corporation including
vital signs monitors utilizing parameters as described above and
additionally monitors which measure non-invasive cardiac output and
hemodynamic status, and fetalgard monitors.
g) Blood Pressure Measurement Technology - includes sales to Original
Equipment Manufacturers ("OEM") of the Company's proprietary non-invasive
blood pressure modules (MAXNIBP(R)), blood pressure cuffs and accessories
for the OEM market and related license fees.
h) Supplies and Service - includes sales of blood pressure cuffs and rapid
infusor cuffs, neonatal intensive care supplies including electrodes and
skin temperature probes, and service repair revenues.
Results of Operations
---------------------
For the three months ended September 30, 2007, the Company reported net
income of $539,000 or $0.05 per diluted common share compared to net income of
$720,000 or $0.06 per diluted common share reported for the three months ended
September 30, 2006. Net income for the three months ended September 30, 2007
includes favorable federal and state tax adjustments of $144,000, or $0.01 per
diluted common share, primarily related to the exchange of state tax
carryforwards for reduced cash payments to the Company. Increases in sales and
marketing spending to support the Company's recent launch of the Fore-Sight
cerebral oximeter and its exclusive worldwide agreement with the Analogic
Corporation to market a co-branded family of vital signs monitors, and increases
in manufacturing costs including start-up costs related to the Fore-sight
cerebral oximeter product line, combined to impact the Company's operating
results for the three months ended September 30, 2007. Pre-tax income for the
three-month periods ended September 30, 2007 and 2006 was also affected by
approximately $86,000 and $98,000, respectively, of stock compensation expense.
Pre-tax income for the three months ended September 30, 2006 was favorably
affected by a reduction in accrued retirement benefit costs of $87,000 related
to changes to the Company's post-retirement health benefit plan during 2005.
Page 13
For the nine months ended September 30, 2007, the Company reported net
income of $318,000 or $0.03 per diluted common share compared to net income of
$1,211,000 or $0.10 per diluted common share for the nine months ended September
30, 2006. Net income for the nine months ended September 30, 2007 includes
favorable federal and state tax adjustments of $144,000, or $0.01 per diluted
common share referred to above. Pre-tax income for the nine-month periods ended
September 30, 2007 and 2006 was also affected by approximately $218,000 and
$299,000, respectively, of stock compensation expense. Increases in Fore-sight
related sales, marketing and manufacturing start-up costs for the first nine
months of 2007, together with shortfalls in year-to-date Original Equipment
Manufacturer ("OEM") sales to a major customer, Medtronic, combined to impact
results for the nine months ended September 30, 2007. The Company has also
incurred approximately $109,000 of consulting expenses during the nine months
ended September 30, 2007 for its Sarbanes Oxley 404 internal controls compliance
project. Pre-tax income for the nine months ended September 30, 2006 was
favorably affected by a reduction in accrued retirement benefit costs of
$262,000 related to changes to the Company's post-retirement health benefit plan
during 2005.
The Company generated revenues of $10,663,000 for the three months ended
September 30, 2007, an increase of $1,237,000 or 13.1%, compared to revenues of
$9,426,000 for the three months ended September 30, 2006. The following table
provides information with respect to revenues by major category:
Three Months Ended Three Months Ended Increase/
($000's) September 30, 2007 September 30, 2006 (Decrease)
---------- ---------- ----------
Low Acuity Products $ 6,058 $ 4,783 $ 1,275
High Acuity Products 80 -- 80
Blood Pressure Measurement Technology 1,231 1,384 (153)
Supplies/Service 3,294 3,258 36
---------- ---------- ----------
$ 10,663 $ 9,426 $ 1,238
========== ========== ==========
Domestic Sales 8,903 7,798 1,105
International Sales 1,760 1,627 133
---------- ---------- ----------
$ 10,663 $ 9,426 $ 1,238
========== ========== ==========
Low acuity product revenues for the three months ended September 30, 2007
were led by an increase in vital signs monitoring and accessories sales of
$1,275,000 or 27% primarily driven by sales to the Department of Veterans
Affairs ("VA") and sales of the Company's co-branded vital signs monitors
developed and manufactured by Analogic Corporation. Blood Pressure Measurement
Technology (OEM) sales decreased approximately $154,000 or approximately 11% due
to reductions in sales to a key customer, Medtronic. During January 2007,
Medtronic announced a voluntary suspension of U.S. product shipments from its
Physio-Control division. Medtronic represented approximately 11% of the
Company's revenues for the full year 2006. Although sales to Medtronic for the
three months ended September 30, 2007 were approximately 20% below sales for the
same three month period of the prior year, the Company's management remains
optimistic that Medtronic sales may return to prior year levels during the
fourth quarter of 2007. High acuity product revenues of $80,000 represent sales
of the Company's Fore-Sight cerebral oximetry monitors and sensors. The Company
began marketing the Fore-Sight technology during the second quarter of 2007.
Sales to the U.S. market accounted for $8,903,000 or 83% of the total
revenues reported for the three months ended September 30, 2007, an increase of
$1,105,000 or 14% over the $7,798 reported for the three months ended September
30, 2006.
Page 14
The Company generated revenues of $27,915,000 for the three months
ended September 30, 2007, an increase of $2,904,000 or 11.6% over revenues of
$25,011,000 for the three months ended September 30, 2006. The following table
provides comparative results by major category:
Nine Months Ended Nine Months Ended Increase/
(000's) September 30, 2007 September 30, 2006 (Decrease)
---------- ---------- ----------
Low Acuity Products $ 13,730 $ 10,550 $ 3,180
High Acuity Products 108 -- 108
Blood Pressure Measurement Technology 3,942 5,185 (1,243)
Supplies/Service 10,135 9,276 859
---------- ---------- ----------
$ 27,915 $ 25,011 $ 2,904
========== ========== ==========
Domestic Sales 21,795 19,484 2,311
International Sales 6,120 5,527 593
---------- ---------- ----------
$ 27,915 $ 25,011 $ 2,904
========== ========== ==========
Revenues for the nine months ended September 30, 2007 were led by sales of
low acuity products which increased $3,180,000 or 30% to $13,730,000 compared to
$10,550,000 for the nine months ended September 30, 2006. Sales of vital signs
monitors to the VA and sales of Analogic products accounted for the increase in
low acuity product sales. Reductions in blood pressure measurement technology
(OEM) sales of $1,243,000 resulted from decreases in sales to Medtronic of
approximately $1,601,000 or 51% over sales recorded for the prior year and were
partially offset by increased sales to other OEM partners. Supplies and service
revenues increased approximately 9% led by increases in sales of blood pressure
cuffs. High acuity product revenues of $108,000 during the nine months ended
September 30, 2007, represent sales of the Company's Fore-Sight technology.
Sales to the U.S. market accounted for $21,795,000 or 78% of the total
revenues reported for the nine months ended September 30, 2007, an increase of
$2,311,000 or 11% over the $19,484,000 reported for the nine months ended
September 30, 2006.
Costs of sales was $6,635,000 or 62.2% of revenues for the three month
period ended September 30, 2007 compared to $5,340,000 or 56.7% for the same
period of 2006. The increase in cost of sales as a percentage of revenues was
related to a number of factors including lost gross margins on the shortfall in
OEM business which carries higher gross margin than other products sold by the
Company, Fore-Sight cerebral oximetry manufacturing start-up costs, increased
blood pressure cuff and accessories sales as a percentage of total revenues
which normally carry lower gross margin rates, increased indirect manufacturing
overhead costs to support the Company's expanded operations and reductions in
accrued post-retirement benefit costs during 2006 for changes made to terminate
the Company's plan during 2005.
Costs of sales for the nine months ended September 30, 2007 was
$17,830,000 or 63.9% of revenues compared to $14,509,000 or 58.0% of revenues
for the nine months ended September 30, 2006. The increase in cost of sales as a
percentage of revenues was related to the factors referred to above including -
OEM lost gross margins, NIRS start-up costs and increased indirect manufacturing
overhead expenses and reductions in accrued post-retirement benefit costs during
2006.
R&D expenses decreased $213,000 or 32.7% to $440,000 or 4.1% of revenues
for the three months ended September 30, 2007 compared to $653,000 or 6.9% of
revenues for the three months ended September 30, 2006 after reimbursements from
the National Institutes of Health ("NIH") pertaining to the Company's
Near-Infrared
Page 15
Spectroscopy ("NIRS") technology. Approximately $181,000 in reimbursement was
received for the three months ended September 30, 2007 under active grants.
Reductions in recruitment fees and stock compensation amortization also
contributed to the decrease in R&D spending after NIH reimbursements. R&D
expenses for the first nine months of 2007 decreased $161,000 or 8.5% to
$1,725,000 or 6.2% of revenues compared to $1,886,000 or 7.5% of revenues for
the first nine months of the prior year. Reimbursements from the NIH aggregated
$360,000 compared to $21,000 for the prior nine months year-to-date and were
partially offset by increases in salaries and related benefits and engineering
project costs related to the NIRS effort. R&D expenses before NIH reimbursements
for the first nine months of 2007 increased $187,000 or 9.3% to $2,085,000 or
7.5% of revenues compared to $1,907,000 or 7.6% of revenues for the same period
of the prior year.
Selling, general and administrative expenses ("S,G&A") increased $676,000
or 29.9% to $2,938,000, representing 27.6% of revenues for the three months
ended September 30, 2007 compared to $2,262,000 or 24.0% of revenues for the
three months ended September 30, 2006. Sales and marketing expenses associated
with the NIRS effort totaled $388,000 and accounted for $218,000 of the increase
in S,G&A expenses. Such expenses included clinical specialist salaries and
related benefits and travel and entertainment expenses and increased tradeshows,
advertising and product sample expenses. Marketing expenses not associated with
the NIRS effort increased $141,000 as a result of increased salaries and related
expenses, product literature costs and facilities expense. The Company also
incurred certain expenses including sales training resulting from its agreement
with Analogic Corporation under which it became the exclusive distributor of a
family of co-branded vital signs monitors developed, manufactured, and
previously marketed by Analogic. Domestic selling expenses accounted for
approximately $183,000 of the increase in S,G&A as a result of increased sales
management salaries expense, commissions and fringe benefits and travel and
entertainment expenses. During 2007, the Company enlarged its domestic sales
management team to support its expanded product offerings including the
co-branded Analogic family of vital signs products, the Fore-sight cerebral
oximetry technology, and the Company's existing products. S,G&A expenses for the
three months ended September 30, 2007 also included $59,000 of consulting fees
pertaining to Sarbanes Oxley Section 404 compliance efforts which were initiated
during the second quarter of 2007 and are expected to continue throughout the
balance of 2007.
S,G&A expenses for the nine months ended September 30, 2007 increased
$1,464,000 or 22.7% to $7,921,000 or 28.4% of revenues compared to $6,457,000 or
25.8% of revenues for the nine months ended September 30, 2006. NIRS related
sales and marketing expenses reached $1,188,000 and accounted for $903,000 or
61.7% of the increase in S,G&A. Other marketing expenses increased $154,000 as a
result of advertising, product literature, samples expenses and facilities
costs. Domestic selling expenses accounted for approximately $262,000 of the
increase in S,G&A as a result of increased sales management, sales
administration and technical support personnel including salaries, commissions
and fringe benefits, travel and entertainment expenses. International sales
expenses accounted for $248,000 of the increase resulting from additional sales
consultant costs and increased travel and entertainment expenses. G&A expenses
declined $156,000 due to reductions in accrued bonuses, stock compensation
expense and Statcorp administrative costs partially offset by increased
insurance costs and $109,000 of Sarbanes-Oxley consulting fees. Prior year S,G&A
expenses were also favorably affected by $63,000 in reductions in accrued
retirement benefit costs related to changes to the Company's post-retirement
health benefit plan during 2005.
Interest expense increased to $71,000 and $189,000, respectively for the
three and nine months ended September 30, 2007 compared to $60,000 and $187,000,
respectively for the three and nine months ending September 30, 2006. The
increase in interest expense resulted primarily from advances under the
Company's line-of-credit partially offset by long-term debt repayments.
The income tax benefit of $69,000 for the nine-months ended September 30,
2007 reflects an exchange of $155,000 of state tax carryforwards for reduced
cash credits payable to the Company. The combined estimated federal and state
effective tax rate for this period is 31% and is lower than the statutory rate
as a result of anticipated state and federal R&D tax credits partially offset by
non-deductible stock compensation expense. The provisions for income taxes for
the nine months ended September 30, 2006 resulted in an effective tax rate of
39% due to non-deductible stock compensation expense partially offset by state
and federal R&D tax credits.
Page 16
Financial Condition, Liquidity and Capital Resources
----------------------------------------------------
At September 30, 2007, the Company's cash and cash equivalents totaled
$699,000 compared to $1,335,000 at December 31, 2006. Working capital increased
by $1,141,000 to $10,384,000 at September 30, 2007, from $9,096,000 on December
31, 2006. The Company's current ratio decreased to 2.21 to 1 from 2.81 to 1.
Cash used by operations for the nine months ended September 30, 2007 was
$2,635,000 compared to cash provided of $48,000 for the first nine months of the
prior year. Increases in inventories of $4,107,000 were largely responsible for
the cash used by operations for the first nine months of 2007 and were primarily
driven by purchases required to support the Fore-sight cerebral oximeter product
launched in May 2007, inventory requirements to support the Analogic products
including sales demonstration goods, and general increases to support customer
orders for vital signs monitors and accessories expected to be shipped during
the beginning of the fourth quarter of 2007. Accounts receivable increases of
$1,508,000 reflect the growth and timing of sales for the third quarter of 2007
compared to sales for the fourth quarter of 2006. Increases in inventory and
accounts receivable were partially offset by increases of $2,374,000 in accounts
payable and accrued expenses.
Cash provided by investing activities was $1,501,000 for the nine months
ended September 30, 2007 compared to cash used of $1,080,000 for the first nine
months of the prior year. Proceeds of $2,802,000 were realized from the sale
leaseback of the Company's headquarters. Expenditures for property and equipment
of $1,013,000 during the nine months ended September 30, 2007 were driven by
Fore-Sight cerebral oximeter demonstration and clinical research units,
information technology and manufacturing equipment. Prior year expenditures
reflected $638,000 of spending for leasehold improvements, manufacturing
equipment and engineering equipment. Spending for intangible assets of $288,000
for the first nine months of 2007 primarily included deposits to secure new
leased office space, contract advances and deferred legal and patent costs.
Cash provided by financing activities for the nine months ended September
30, 2007 was $498,000 compared to cash used of $165,000 for the first nine
months of the prior year. Advances from the Company's line-of-credit of
$1,200,000 were primarily responsible for the increase in cash provided by
financing activities. The Company also realized proceeds of $226,000 from the
issuance of common stock related to the exercise of stock options and warrants,
federal and state income tax benefits of $380,000 from the exercise of the
warrants, and $329,000 from insurance notes. During the first nine months of
2007, the Company repaid $448,000 of long-term debt and $260,000 of insurance
notes and retired its mortgage debt of $929,000 upon the sale of its
headquarters.
For the remainder of 2007, the Company expects to sustain its spending
associated with the NIRS cerebral oximetry technology and the related Fore-Sight
oximeter market penetration. Such spending includes additional R&D, on-going
clinical studies, sales and marketing expenses, and capital expenditures. The
Company believes that its sources of funds consisting of cash and cash
equivalents and funds available from the revolving credit facility will be
sufficient to meet its current and expected short-term requirements. The Company
may also pursue other financing alternatives to meet its capital needs and
believes that, if needed, it would be able to find additional sources of funds
on commercially acceptable terms which may be required to support the Company's
long-term initiatives.
Critical Accounting Policies and Estimates
------------------------------------------
The Company's discussion and analysis of financial condition and results
of operations are based on the condensed financial statements. The preparation
of these financial statements requires the Company to make estimates and
judgments that affect the amounts reported in them. The Company's critical
accounting policies and estimates include those related to revenue recognition,
the valuations of inventories and deferred income tax assets, measuring stock
compensation, post-retirement health benefit, and warranty costs, determining
useful lives of intangible assets, and making asset impairment valuations. The
Company bases its estimates on historical experience and on various other
assumptions that management believes to be reasonable under the circumstances.
Actual results may differ from these estimates under different assumptions or
conditions. For additional information about the Company's critical accounting
policies and estimates, see Note 3 to the financial statements included in the
Company's Form 10-KSB for the
Page 17
year ended December 31, 2006. There were no significant changes in critical
accounting policies and estimates during the three months ended September 30,
2007.
New accounting pronouncements and the Company's assessment of their impact
on the financial statements are disclosed in Note 8 to the notes to condensed
consolidated financial statements contained herein.
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
------ ----------------------------------------------------------
In the normal course of business, the Company is exposed to fluctuations
in interest rates and fluctuations in foreign currency exchange rates. We do not
use derivative instruments or hedging to manage our exposures and do not
currently hold any market risk sensitive instruments for trading purposes.
ITEM 4T CONTROLS AND PROCEDURES
------- -----------------------
The Company maintains disclosure controls and procedures that are designed
to ensure that information required to be disclosed in the Company's Exchange
Act reports is recorded, processed, summarized and reported within the time
periods specified in the SEC's rules and forms, and that such information is
accumulated and communicated to the Company's management, including its Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure based on the definition of "disclosure
controls and procedures" in Rule 13a-15(e). In designing and evaluating the
disclosure controls and procedures, management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and management
necessarily is required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.
The Company carried out an evaluation, under the supervision and with the
participation of the Company's management, including the Company's Chief
Executive Officer and the Company's Chief Financial Officer, of the
effectiveness of the design and operation of the Company's disclosure controls
and procedures as of September 30, 2007. Based upon the foregoing evaluation,
the Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective as of that date.
There have been no changes in the Company's internal control over
financial reporting during the quarter ended September 30, 2007 that have
materially affected, or are reasonably likely to materially affect the Company's
internal control over financial reporting.
Reference is made to the Certifications of the Chief Executive Officer and
the Chief Financial Officer about these and other matters attached as Exhibits
31.1, 31.2 and 32.1 to this report.
Page 18
PART II - OTHER INFORMATIION
----------------------------
ITEM 1 LEGAL PROCEEDINGS
------ -----------------
The manufacture and sale of our products exposes us to product liability
claims and product recalls, including those which may arise from misuse or
malfunction of, or design flaws in, our products or use of our products with
components or systems not manufactured or sold by us. Product liability claims
or product recalls, regardless of their ultimate outcome, could require us to
spend significant time and money in litigation or to pay significant damages. We
are currently a defendant in two pending product liability actions, one of which
is scheduled for trial in February 2008. Although we believe that our product
liability insurance is sufficient to cover any damages and costs that are likely
with respect to these matters, there can be no assurance that this will be the
case with respect to the pending matters or any future matters. Furthermore, we
may not be able to obtain insurance in the future at satisfactory rates or in
adequate amounts. In addition, publicity pertaining to the misuse or malfunction
of, or design flaws in, our products could impair our ability to successfully
market and sell our products and could lead to product recalls.
In addition, we may become, in the normal course of our business
operations, a party to other legal proceedings in addition to those described in
the paragraph above. None of these other proceedings would be expected to have a
material adverse impact on our results of operations, financial condition, or
cash flows.
ITEM 6 EXHIBITS
------ --------
31.1 Certification pursuant to Rule 13a-14(a) of Andrew E. Kersey, President
and Chief Executive Officer
31.2 Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief
Financial Officer
32.1 Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report
of Andrew E. Kersey, President and Chief Executive Officer and Jeffery
A. Baird, Chief Financial Officer
Page 19
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CAS MEDICAL SYSTEMS, INC.
-------------------------
(Registrant)
/s/ Andrew E. Kersey Date: November 13, 2007
-----------------------------------------
By: Andrew E. Kersey
President and Chief Executive Officer
/s/ Jeffery A. Baird Date: November 13, 2007
-----------------------------------------
By: Jeffery A. Baird
Chief Financial Officer